Zobrazeno 1 - 10
of 185
pro vyhledávání: '"Shoichiro Ohtani"'
Autor:
Javier Cortes, Eric P Winer, Oleg Lipatov, Seock‐Ah Im, Anthony Gonçalves, Eva Muñoz‐Couselo, Keun Seok Lee, Peter Schmid, Kenji Tamura, Laura Testa, Isabell Witzel, Shoichiro Ohtani, Stephanie Hund, Karina Kulangara, Vassiliki Karantza, Jaime A Mejia, Junshui Ma, Petar Jelinic, Lingkang Huang, Scott K Pruitt, Kenneth Emancipator
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 10, Iss 3, Pp n/a-n/a (2024)
Abstract The efficacy of pembrolizumab monotherapy versus chemotherapy increased with increasing programmed death ligand 1 (PD‐L1) expression, as quantified by combined positive score (CPS; PD‐L1 expression on both tumour cells and immune cells)
Externí odkaz:
https://doaj.org/article/42c035448af94e8fbfc51bd921ef67f3
Autor:
Misato Masuyama, Norikazu Masuda, Hidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Toshinari Yamashita, Daisuke Yotsumoto, Masakazu Toi, Shinji Ohno
Publikováno v:
Cancer Medicine, Vol 12, Iss 17, Pp 17718-17730 (2023)
Abstract Background The role of endocrine therapy in the treatment of patients in a postmenopausal hormonal state and with estrogen receptor (ER)‐positive, human epidermal growth factor receptor 2 (HER2)‐positive advanced or metastatic breast can
Externí odkaz:
https://doaj.org/article/caeec8fc425642ad8dfd47e91b38c921
Autor:
Takayuki Ueno, Shigehisa Kitano, Norikazu Masuda, Daiki Ikarashi, Makiko Yamashita, Tomohiro Chiba, Takayuki Kadoya, Hiroko Bando, Takashi Yamanaka, Shoichiro Ohtani, Shigenori Nagai, Takahiro Nakayama, Masato Takahashi, Shigehira Saji, Kenjiro Aogi, Ravi Velaga, Kosuke Kawaguchi, Satoshi Morita, Hironori Haga, Shinji Ohno, Masakazu Toi
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-10 (2022)
Abstract Background Triple-negative breast cancer (TNBC) is a biologically diverse disease, with characteristics such as homologous recombination deficiency (HRD), gene mutation, and immune reactions. Japan Breast Cancer Research Group 22 is a multic
Externí odkaz:
https://doaj.org/article/5711388d449949039bda369d7ffea37a
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Eribulin methylate (eribulin) improved the overall survival (OS) of eribulin-treated patients with HER2-negative advanced breast cancer (ABC) in prospective and retrospective studies. However, the effect of eribulin on OS as first
Externí odkaz:
https://doaj.org/article/c0dea0975b144769825cbd927e481ae6
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract Post-progression survival affects overall survival (OS) in patients with HER2-negative advanced breast cancer (HER2-ABC); thus, the optimal choice of first-line chemotherapy (1LCT) remains controversial. We investigated patients with HER2-AB
Externí odkaz:
https://doaj.org/article/86285e9b6b9e4519a0e2732749a6ffd2
Autor:
Takahiro Nakayama, Tetsuhiro Yoshinami, Hiroyuki Yasojima, Nobuyoshi Kittaka, Masato Takahashi, Shoichiro Ohtani, Seung Jin Kim, Hiroyuki Kurakami, Naoko Yamamoto, Tomomi Yamada, Takehiko Takata, Norikazu Masuda
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background Trastuzumab emtansine (T-DM1) is a second-line standard therapy for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Evidence regarding post–T-DM1 treatments is currently lacking.
Externí odkaz:
https://doaj.org/article/8b02d3fbc4a34996b43ef5c3f608feda
Autor:
Miwa Fujihara, Rie Yamasaki, Mitsuya Ito, Tadahiko Shien, Reina Maeda, Takanori Kin, Ayako Ueno, Yukiko Kajiwara, Kensuke Kawasaki, Kouichi Ichimura, Hiroya Mihara, Naritaka Kimura, Shoichiro Ohtani
Publikováno v:
BMC Women's Health, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background The number of patients desiring implant-based breast reconstruction has been increasing. While local recurrence is observed in patients with breast reconstruction, only a few reports have focused on the risk factors for local recu
Externí odkaz:
https://doaj.org/article/e4df50a33c554a9c93f3ea5c38a86d4b
Autor:
Tsutomu Iwasa, Junji Tsurutani, Satomi Watanabe, Ryoji Kato, Yutaka Mizuno, Yasuyuki Kojima, Tsutomu Takashima, Nobuki Matsunami, Takashi Morimoto, Jun Yamamura, Shoichiro Ohtani, Yuko Tanabe, Tetsuhiro Yoshinami, Toshimi Takano, Yoshifumi Komoike, Kazuhiko Nakagawa
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
Abstract Background We previously reported the synergistic effect of S-1 and eribulin in preclinical models. In addition, our phase I study revealed the recommended dose for the phase II study of the combination therapy in advanced breast cancer (ABC
Externí odkaz:
https://doaj.org/article/0a03588daea444e08474b844baa4c3b0
Autor:
Seock-Ah Im, Hirofumi Mukai, In Hae Park, Norikazu Masuda, Chikako Shimizu, Sung-Bae Kim, Young-Hyuck Im, Shoichiro Ohtani, Cynthia Huang Bartlett, Dongrui R. Lu, Shrividya Iyer, Yuko Mori, Ave Mori, Eric Gauthier, Richard S. Finn, Masakazu Toi
Publikováno v:
Journal of Global Oncology, Vol 5, Pp 1-19 (2019)
PURPOSE: In PALOMA-2, palbociclib plus letrozole significantly improved progression-free survival (PFS) as initial treatment of estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer. We assessed the b
Externí odkaz:
https://doaj.org/article/27c93162d478480fa223e9d92b076529
Autor:
Ryungsa Kim, Ami Kawai, Megumi Wakisaka, Sayaka Sawada, Mika Shimoyama, Naomi Yasuda, Masayuki Hidaka, Yukitaka Morita, Shoichiro Ohtani, Mitsuya Ito, Kensuke Kawasaki, Takanori Kin, Koji Arihiro
Publikováno v:
Translational Oncology, Vol 14, Iss 1, Pp 100927- (2021)
Immune activation plays an important role in achieving the pathological and therapeutic effects of preoperative chemotherapy in patients with breast cancer. We evaluated how the immune response contributes to various therapeutic effects. This study w
Externí odkaz:
https://doaj.org/article/e7682bb98d63462684d461968eb0c2dc